Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes
Phase 1
- Conditions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2007-03-12
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 39
- Registration Number
- NCT00411905
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷CHU Dijon, Dijon, France
🇫🇷CHU Purpan, Toulouse, France
© Copyright 2024. All Rights Reserved by MedPath